Study Supports Longer ADT Use With Radiation for High-Risk Prostate Cancer
Study findings suggest a longer ADT duration than NCCN guidelines for patients with high-risk prostate cancer treated with EBRT alone.
Androgen-deprivation Therapy
Prostate Cancer ADT Has Fewer Cardiovascular Risks Than Expected
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
Adding Anti-Androgens to Late Salvage RT May Improve PCa Outcomes
Concomitant anti-androgen therapy may ameliorate the worse outcomes associated with delayed salvage radiation therapy for recurrent prostate cancer after radical surgery.
Apalutamide Improves rPFS in Metastatic Castration-Resistant Prostate Cancer
The median rPFS was 24.0 months in the apalutamide arm and 16.6 months in the placebo arm.
Androgen Signaling Inhibitors Appear More Effective in Luminal Metastatic Castration-Resistant Prostate Cancer
Patients with basal tumors did not derive a significant survival benefit from androgen signaling inhibitors.
Abiraterone Added to ADT Improves Prostate Cancer Outcomes
Using abiraterone plus prednisolone with standard androgen deprivation therapy should be considered a new standard of care for patients with high-risk nonmetastatic prostate cancer, according to investigators.
Enzalutamide Shown to Slow Progression of Localized Prostate Cancer
A phase 2 exploratory study of men with low- and intermediate-risk localized prostate cancer demonstrated the oncologic benefit of enzalutamide treatment vs active surveillance.
Study: Delaying ADT for Recurrent Prostate Cancer May Not Worsen Survival
Investigators question initiation of continuous androgen deprivation therapy (ADT) for biochemically recurrent prostate cancer without metastasis.
EBRT + Androgen Suppression Improves Outcomes in Intermediate-Risk PCa
A 6-month course of androgen suppression added to external beam radiation therapy increased long-term event-free and disease-free survival compared with EBRT alone, a study found.
Prostate Cancer Mortality Risk Factors After Brachytherapy for Gleason 3+4 Identified
Addition of ADT to brachytherapy may not improve cancer-specific survival among some men with Gleason 3+4 prostate cancer.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...